Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide.


Updates from The Motley Fool

Latest updates on Gilead Sciences from Fool.com.  The Fool has written over 1100 articles on Gilead Sciences.
Why Gilead Sciences Is a Buy

Pitting gene-sequencing specialist Illumina against biotech Gilead Sciences to see which company ...

4 Stocks to Buy Near 52-Week Lows

Interested in finding a bargain in today's overheated market? Consider giving these four cheap st...



Stock Performance

View Interactive GILD Charts
Sponsored by

Key Data Points

Primary metrics and data points about Gilead Sciences.
Current Price: $67.26
Prev Close: $67.10
Open: $67.10
Bid: $67.16
Ask: $67.26
Day's Range: $66.91 - $67.56
52wk Range: $65.38 - $103.10
Volume: 7,224,350
Avg Vol 9,215,850
Market Cap: $88B
P/E (ttm): 6.75
EPS (ttm): $9.94
Div & Yield: $2.08 (3.1%)

Company Rating

What our community thinks about Gilead Sciences.
CAPS Rating 5 out of 5
 
3653 Outperform
86 Underperform
CAPS All Stars
 
764 Outperform
14 Underperform

How do you think Gilead Sciences will perform against the market?



You pick for Gilead Sciences is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

John Milligan, CEO

81% Approve

Based on 43 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Gilead Sciences.

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers